T-Cell Therapy + Vaccine + Drugs for Acute Myeloid Leukemia

This trial aims to determine if a new combination treatment is safe and effective for people with acute myeloid leukemia (AML). The treatment includes a special T-cell therapy (a type of immune cell), a vaccine (DC/AML Fusion Vaccine), and two drugs commonly used for AML—decitabine and venetoclax. It evaluates whether these components work well together to fight leukemia. People with AML who plan to use decitabine and venetoclax as part of their regular treatment might be a good fit for this trial. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

The trial does not specify if you need to stop taking your current medications, but you cannot use immunosuppressive medication within 14 days before the first T cell infusion. Some exceptions apply, like certain types of steroids.

Research has shown that treatments in this clinical trial have demonstrated varying levels of safety in past studies. The DC/AML fusion vaccine, which boosts the immune system, has generally been well-tolerated. One study found that the most common side effects were mild reactions at the injection site. However, a few patients developed a more serious condition called graft-versus-host disease (GVHD), where donor cells attack the patient's body.

For the DC/AML primed T cells, specific safety information is limited. However, similar T-cell therapies have shown promise in being safe and effective for some patients with leukemia.

Decitabine and venetoclax, both FDA-approved for other uses, have been used together before. Decitabine is known to work well and is usually well-tolerated, with manageable side effects. Venetoclax also has a predictable safety profile, with no new safety concerns in recent studies on AML.

Researchers are excited about these treatments for Acute Myeloid Leukemia (AML) because they combine innovative approaches that differ from standard chemotherapy. Unlike traditional treatments, which primarily use chemotherapy to kill cancer cells, this regimen harnesses the power of the immune system. The DC/AML fusion vaccine and DC/AML primed T cells are designed to train the body's immune cells to specifically target and eliminate leukemia cells, offering a more tailored attack on the cancer. Additionally, the use of Decitabine and Venetoclax helps to sensitize the cancer cells, making them more vulnerable to immune attack. This combination of targeted immune therapy and sensitizing drugs represents a promising new direction in AML treatment.

Research shows that the DC/AML fusion vaccine, which participants in this trial may receive, can help the immune system combat acute myeloid leukemia (AML), potentially leading to remission. Studies have found that it can prolong the period without disease progression and increase overall survival rates. The DC/AML primed T cells, another treatment option in this trial, guide the immune system to locate and destroy AML cells. Previous research indicates that T-cell therapies can lead to long-lasting remission. Decitabine, part of the treatment regimen in this trial, has improved outcomes in older AML patients by increasing survival rates. Venetoclax, also included in the trial, has achieved complete remission in AML when combined with other treatments. These treatments work together in this trial to fight AML by boosting the immune response and directly attacking cancer cells.¹⁶⁷⁸⁹